Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Medical Dermatology Potpourri
Description
In the talk titled "Medical Dermatology Potpourri," speakers Arash Mastagami and Caroline Nelson engage with the audience about recent developments in dermatology. They discuss the evolving landscape of dermatological treatments, focusing on a paradigm shift from solely targeting specific inflammatory cytokines to adopting a broader immune regulation approach. Mastagami emphasizes the historical focus on treating conditions like psoriasis through targeted biologics that are costly yet require long-term management. He suggests that newer research may support the development of therapies aimed at regulating the immune system rather than simply suppressing it. This includes mentioning OX40 signaling pathways and the potential for T regulatory cell enhancement. The discussion also covers emerging treatments for conditions like atopic dermatitis and alopecia areata, noting the importance of early intervention and the potential for long-lasting responses from innovative therapies. Mastagami raises critical questions regarding treatment goals, safety profiles, and patient management consent related to ongoing therapies and their implications. The session concludes with an interactive Q&A segment, encouraging discussion on the future of dermatological practice.
View moreConclusions
- A paradigm shift is occurring in dermatology from targeting specific cytokines to a broader approach of immune regulation.
- Current targeted biologic therapies are effective but costly, requiring long-term use and management.
- Stopping targeted biologic therapy often results in disease recurrence, emphasizing the need for consistent treatment.
- Exploring immune regulation rather than suppression may improve disease management and reduce the long-term burden of treatments.
- Innovations like the OX40 pathway may offer new avenues for treatment by focusing on reducing chronic inflammation rather than just suppressing individual cytokines.
- Initial results from studies on OX40 inhibitors and the IL-2 agonist Rezpeg suggest promising outcomes in terms of disease control and management of chronic conditions.
- Future biologic therapies may incorporate multi-specific agents targeting several cytokines simultaneously to enhance efficacy and reduce treatment burden.
- Long-term safety and effectiveness of new treatment strategies remain an essential question that requires further research.
- Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M. Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: a Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study. 2024. https://doi.org/10.1007/s12325-023-02755-z
- Mostaghimi A, Soliman AM, Li C, et al. Comorbidities Among Patients Newly Diagnosed With Alopecia Areata. JAMA Dermatol. 2024;160(9):945-952. doi:10.1001/jamadermatol.2024.2404
- King B et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. NEJM. 2021. DOI: 10.1056/NEJMoa2110343
- Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017: 13:234.